FY guidance is $1.4b. HY1 is $677.4m. Your guess about chinese label revenue of $495 is also in line with what company said - they expect ~40-45% growth to continue for that segment. If to assume there is no growth/decline in any other segment it will give us ~$1.42b for the FY. So, even if they sell less IF in CBEC & ANZ by $20m this HY they still will meet the guidance. So, yes, lets hope they can do better in CBEC & ANZ in 2HY
Btw, if to believe a2nutrition.cn site they already increase their store count by 8k.
- Forums
- ASX - By Stock
- A2M
- Chart Update
Chart Update, page-18316
-
- There are more pages in this discussion • 6,915 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.85 |
Change
-0.030(0.44%) |
Mkt cap ! $4.959B |
Open | High | Low | Value | Volume |
$6.93 | $6.98 | $6.83 | $10.27M | 1.490M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 18844 | $6.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.85 | 41602 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 18844 | 6.840 |
3 | 11592 | 6.830 |
6 | 24590 | 6.820 |
6 | 12426 | 6.810 |
4 | 8948 | 6.800 |
Price($) | Vol. | No. |
---|---|---|
6.850 | 41602 | 1 |
6.860 | 1762 | 2 |
6.870 | 10548 | 4 |
6.880 | 19288 | 5 |
6.890 | 19104 | 4 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online